Mutations in tumor protein 53 (TP53) and Titin (TTN) genes play pivotal roles in LUAD, influencing tumor aggressiveness and prognosis, and the patient’s response to treatments, including chemotherapy and immunotherapy[10,11]. This evidence concerns the gene TTN and neoplasm.